



Oct 24, 2023

Company Name:	GNI Group Ltd.
Representative:	Director, Representative Executive Officer, President and CEO Ying Luo, PhD (Security Code: 2160, TSE Growth)
Contact Person:	Chief Financial Officer Toshiya Kitagawa (TEL. 03-6214-3600)

Disclosure by Catalyst Biosciences on The Transaction with GNI Group

As GNI Group Co., Ltd. ("GNI" or "we") disclosed on October 23, 2023, Form 8K on the transaction with GNI, which GNI first disclosed on December 27, 2022, was filed by Catalyst Biosciences, Inc. ("CBIO"), a Nasdaq-listed company.

The Form 8K which CBIO has released can be found on the CBIO website at

<https://ir.catalystbiosciences.com/node/15286/html>

In Form 8K, CBIO states that CBIO and the GNI Entities expect the transaction to close by the Outside Date (as defined in the Agreement), which is October 30.

The impact of this transaction on the Group's consolidated financial results for the current fiscal year is being evaluated and will be disclosed when it is clear.

This material contains statements concerning the current plans, expectations and strategies of GNI Group Ltd. ("the Company"). Any statements contained herein that pertain to future operating performance and that are not historic facts are forward-looking statements. Forward-looking statements may include, but are not limited to, words such as "believe," "plan," "strategy," "expect," "forecast," "possibility" and similar words that describe future operating activities, business performance, events or conditions. Forward-looking statements, whether spoken or written, are based on judgments made by the management of the Company, based on information that is currently available to it. As such, these forward-looking statements are subject to various risks and uncertainties, and actual business results may vary substantially from the forecasts expressed or implied in forward-looking statements. Consequently, investors are cautioned not to place undue reliance on forward-looking statements.

The information contained in this material does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Any decision to invest in or acquire securities of the Company must be based wholly on the information contained in the preliminary offering circular issued or to be issued by the Company in connection with any such offer and not on the contents hereof.